News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,172 Results
Type
Article (45082)
Company Profile (721)
Press Release (686360)
Multimedia
Podcasts (153)
Webinars (25)
Section
Business (211483)
Career Advice (2700)
Deals (37115)
Drug Delivery (136)
Drug Development (82517)
Employer Resources (179)
FDA (16561)
Job Trends (15853)
News (356145)
Policy (32692)
Tag
Academia (2167)
Academic (2)
Accelerated approval (33)
Adcomms (28)
Allergies (141)
Alliances (51988)
ALS (178)
Alzheimer's disease (1706)
Antibody-drug conjugate (ADC) (329)
Approvals (16777)
Artificial intelligence (547)
Autoimmune disease (150)
Automation (31)
Bankruptcy (384)
Best Places to Work (11769)
BIOSECURE Act (23)
Biosimilars (189)
Biotechnology (449)
Bladder cancer (153)
Brain cancer (59)
Breast cancer (621)
Cancer (4774)
Cardiovascular disease (418)
Career advice (2284)
Career pathing (41)
CAR-T (285)
CDC (37)
Cell therapy (773)
Cervical cancer (36)
Clinical research (70240)
Collaboration (1738)
Company closure (5)
Compensation (1118)
Complete response letters (68)
COVID-19 (2712)
CRISPR (92)
C-suite (830)
Cystic fibrosis (151)
Data (6071)
Decentralized trials (2)
Denatured (47)
Depression (139)
Diabetes (507)
Diagnostics (6894)
Digital health (41)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (260)
Drug pricing (206)
Drug shortages (34)
Duchenne muscular dystrophy (229)
Earnings (91110)
Editorial (60)
Employer branding (24)
Employer resources (158)
Events (122102)
Executive appointments (1008)
FDA (19591)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (9)
Frontotemporal dementia (23)
Funding (1486)
Gene editing (205)
Generative AI (54)
Gene therapy (632)
GLP-1 (1080)
Government (4168)
Grass and pollen (8)
Guidances (378)
Healthcare (18427)
HIV (57)
Huntington's disease (47)
IgA nephropathy (85)
Immunology and inflammation (275)
Immuno-oncology (55)
Indications (87)
Infectious disease (2976)
Inflammatory bowel disease (196)
Inflation Reduction Act (15)
Influenza (111)
Intellectual property (239)
Interviews (522)
IPO (17442)
IRA (54)
Job creations (4486)
Job search strategy (1866)
JPM (59)
Kidney cancer (15)
Labor market (80)
Layoffs (644)
Leadership (37)
Legal (8224)
Liver cancer (92)
Longevity (13)
Lung cancer (647)
Lymphoma (362)
Machine learning (42)
Management (62)
Manufacturing (796)
MASH (169)
Medical device (14385)
Medtech (14433)
Mergers & acquisitions (20715)
Metabolic disorders (1333)
Multiple sclerosis (153)
NASH (20)
Neurodegenerative disease (338)
Neuropsychiatric disorders (89)
Neuroscience (2953)
Neurotech (1)
NextGen: Class of 2026 (6776)
Non-profit (3797)
Now hiring (64)
Obesity (649)
Opinion (322)
Ovarian cancer (162)
Pain (197)
Pancreatic cancer (228)
Parkinson's disease (279)
Partnered (36)
Patents (488)
Patient recruitment (462)
Peanut (60)
People (61347)
Pharmaceutical (134)
Pharmacy benefit managers (29)
Phase I (21918)
Phase II (30992)
Phase III (23318)
Pipeline (4769)
Policy (294)
Postmarket research (2432)
Preclinical (9180)
Press Release (66)
Prostate cancer (233)
Psychedelics (49)
Radiopharmaceuticals (291)
Rare diseases (844)
Real estate (6216)
Recruiting (76)
Regulatory (24604)
Reports (44)
Research institute (2099)
Resumes & cover letters (418)
Rett syndrome (26)
RNA editing (20)
RSV (76)
Schizophrenia (154)
Series A (256)
Series B (192)
Service/supplier (27)
Sickle cell disease (100)
Special edition (25)
Spinal muscular atrophy (159)
Sponsored (41)
Startups (4003)
State (2)
Stomach cancer (20)
Supply chain (109)
Tariffs (96)
The Weekly (104)
Vaccines (1031)
Venture capital (93)
Weight loss (445)
Women's health (76)
Worklife (21)
Date
Today (61)
Last 7 days (361)
Last 30 days (2047)
Last 365 days (31497)
2026 (1946)
2025 (31679)
2024 (36742)
2023 (41461)
2022 (52107)
2021 (56089)
2020 (54104)
2019 (46689)
2018 (35529)
2017 (34218)
2016 (33344)
2015 (38983)
2014 (32405)
2013 (27736)
2012 (29038)
2011 (29045)
2010 (27057)
Location
Africa (875)
Alabama (87)
Alaska (6)
Arizona (259)
Arkansas (12)
Asia (44089)
Australia (7284)
California (11234)
Canada (3228)
China (1122)
Colorado (472)
Connecticut (486)
Delaware (336)
Europe (98256)
Florida (1620)
Georgia (353)
Hawaii (4)
Idaho (62)
Illinois (850)
India (65)
Indiana (532)
Iowa (24)
Japan (410)
Kansas (124)
Kentucky (38)
Louisiana (26)
Maine (78)
Maryland (1320)
Massachusetts (8278)
Michigan (344)
Minnesota (643)
Mississippi (6)
Missouri (133)
Montana (34)
Nebraska (26)
Nevada (120)
New Hampshire (82)
New Jersey (3034)
New Mexico (32)
New York (2944)
North Carolina (1541)
North Dakota (10)
Northern California (5411)
Ohio (331)
Oklahoma (22)
Oregon (50)
Pennsylvania (2250)
Puerto Rico (21)
Rhode Island (50)
South America (1252)
South Carolina (62)
South Dakota (1)
Southern California (4301)
Tennessee (165)
Texas (1721)
United States (40061)
Utah (325)
Vermont (1)
Virginia (273)
Washington D.C. (82)
Washington State (937)
West Virginia (4)
Wisconsin (118)
Wyoming (2)
732,172 Results for "eli lilly and company".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery
January 12, 2026
·
2 min read
Mergers & acquisitions
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
·
2 min read
·
Tristan Manalac
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.
January 5, 2026
·
3 min read
·
Annalee Armstrong
Obesity
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
December 18, 2025
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
·
3 min read
·
Heather McKenzie
Business
JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient access improves.
January 14, 2026
·
2 min read
·
Nick Paul Taylor
Legal
Compounder Sues Lilly, Novo, Claims Coordinated Crackdown
Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers in exclusive partnerships, disallowing them from offering compounded versions of GLP-1 medicines.
January 15, 2026
·
2 min read
·
Tristan Manalac
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
·
1 min read
·
Heather McKenzie
Press Releases
Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia
November 20, 2025
·
3 min read
Obesity
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.
January 6, 2026
·
2 min read
·
Heather McKenzie
1 of 73,218
Next